Search Results
Sep 08, 2026, 08:00 ET Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program.Genprex's preclinical diabetes program is
More news about: Genprex, Inc.
Sep 08, 2026, 08:00 ET Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO")
More news about: Intensity Therapeutics Inc.
Sep 08, 2026, 08:00 ET NanoMosaic Joins Mass General Brigham-Led Consortium Awarded ARPA-H GIVE Program to Advance On-Demand Distributed Manufacturing of Genetic Medicines
development and manufacturing and to accelerate the discovery and development of biomarkers for a wide range of applications, including disease diagnosis, drug discovery, and precision medicine.Media ContactsNanoMosaic, Inc.Paul BerningSenior Director, Sales and Business
More news about: NanoMosaic
Sep 08, 2026, 08:00 ET Peptide Tracker Rolls Out Major Update Wave: Split Dosing, Custom Compound Library, and Personalized Organization Tools
Setup (v2.15.0) When setting up a protocol, the app now asks how a dose is measured and only shows the matching units, preventing mix-ups between drug amount and syringe marks. Users can also split a dose across two vials when a single vial doesn't hold enough liquid. The app walks users through drawing
More news about: Peptide Tracker
Sep 08, 2026, 08:00 ET Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress
in lung function, increasingly sensitive CT quantification results may help detect subtle treatment effects and support more efficient, data-informed drug development.These positive results have catalyzed further collaboration between Brainomix and Endeavor BioMedicines, aiming to incorporate quantitative
More news about: Brainomix
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.A supplemental New Drug Application (sNDA) for CAPLYTA® with long-term data evaluating the safety and efficacy of the medication for delayed time to relapse in schizophrenia
More news about: Johnson & Johnson
Sep 08, 2026, 08:00 ET Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation
More news about: Abbott
Sep 08, 2026, 07:45 ET TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
of patients with AML. TuHURA is also leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting MDSCs to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired
More news about: TuHURA Biosciences, Inc.
Sep 08, 2026, 07:05 ET UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc.
alleges that Unicycive failed to properly inspect its third-party vendor's manufacturing facility to ensure it resolved the U.S. Food and Drug Administration's ("FDA") previously noted deficiencies.Investors who suffered significant losses during the Class Period may be eligible to participate
More news about: Robbins LLP
Sep 08, 2026, 07:00 ET Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and
More news about: Compugen Ltd.
Sep 08, 2026, 07:00 ET Israel National Biotech Innovation Center (INBI) Announces Official Launch and the Appointment of Anat Cohen-Dayag, PhD, as Chief Executive Officer of INBI Core
advance an exceptional portfolio of promising Israeli biomedical research programs. It will build a world-class team with deep expertise in early-stage drug development, provide the necessary infrastructure and funding and unlock capital and commercialization opportunities for the next generation of Israeli
More news about: Israel National Biotech Innovation Center
Sep 08, 2026, 06:59 ET Carboxymethylcellulose Calcium Market worth $0.09 billion by 2036 - Exclusive Report by MarketsandMarkets™
oral and topical drug formulations, where carboxymethylcellulose calcium helps improve formulation consistency, viscosity, and product stability. In addition, the growing pharmaceutical manufacturing base across emerging economies is creating opportunities for excipient suppliers as drug production and
More news about: MarketsandMarkets
Sep 08, 2026, 06:45 ET New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgical pain studies
of rigorous clinical development behind TYLENOL® with Naproxen, a new, non-opioid, OTC combination pain relief medicine approved by the U.S. Food and Drug Administration (FDA) in July 2026.
More news about: Kenvue Inc.
Sep 08, 2026, 06:30 ET Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving,
More news about: Caris Life Sciences
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
oral tablets (oral amylin receptor peptide agonist) for the treatment of obesity after recently receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
的口服小分子和長效注射劑項目，ASC36進一步強化了我們的多元化產品管線，以滿足肥胖症及其他代謝疾病患者不斷變化的治療需求。」ASC36是一款利用歌禮專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）技術自主研發的胰澱素受體激動劑多肽。ASC36口服片劑由歌禮利用其專有的口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT）開發並優化而成，該技術用於實現口服多肽遞送。在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7天後，穩態下的絕對口服生物利用度（absolute
More news about: 歌禮製藥有限公司
Sep 08, 2026, 04:17 ET Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery
advance BAFA into Phase 2b development. "In our short proof-of-concept study aimed at showing an immediate calcium balance-effect of our drug candidate, BAFA produced coherent biological effects on markers of calcium homeostasis," says Dr. Ville Wallenius, MD, PhD, Adjunct Professor
More news about: Epicyt Pharma AB
Sep 08, 2026, 04:05 ET /C O R R E C T I O N -- GCCL/
explored opportunities to expand its clinical sample analysis and assay development services across the Asia-Pacific region.The company engaged with drug developers working across a broad range of therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based
More news about: GCCL
Sep 08, 2026, 02:08 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Sep 07, 2026, 13:46 ET Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Sep 07, 2026, 13:22 ET Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline
CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory
More news about: Hagens Berman Sobol Shapiro LLP
Sep 07, 2026, 11:06 ET Stem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research
is being driven by rising interest in regenerative medicine, wider use of cell-based therapies, and growing reliance on stem cells for drug discovery and biomedical research. An aging population coupled with a heavier burden of chronic and degenerative conditions is pushing healthcare systems
More news about: Wissen Research LLC
Sep 07, 2026, 10:31 ET Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight
11.2.1Drug Description11.2.2
More news about: DelveInsight Business Research, LLP
Sep 07, 2026, 10:15 ET Cold Plasma Market worth $3.03 billion by 2031 - Exclusive Report by MarketsandMarkets™
Wastewater Surveillance Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets
Sep 07, 2026, 10:01 ET Laboratory Glassware Market worth $9,170 million by 2031 - Exclusive Report by MarketsandMarkets™
market is driven by increasing applications in clinical use, pharmaceutical and drug-discovery research, veterinary science, agriculture, biology, and biotechnology. The growing prevalence of chronic diseases has supported new drug development, while increasing research in vaccine development, disease research,
More news about: MarketsandMarkets